Anavex Life Sciences Corp (AVXL)

[nidan7500]

Of course this board has been through many ups and downs over past few years.....BUT. If A2-73 AD is the first to get RWE/data/results from new trials IMO a massive flashover will impact other trials/indications bias to succeed. Everything w/A2-73 written on it will become golden.

At first I was convinced the RETT choice was a good one for 1st b/c of quick read/turnaround. Then we would see a bias to other tougher trials w/a kind of snowballing based on precision science and Biomarker-Homeostasis readout.

Now, he will speak to findings at AAIC AND will have an AD trial ready to start. From a (BUY THE RUMOR) standpoint the AD (AAIC) RETT-PD sequence makes more sense. He will be able to describe why and what the biomarker prescreening is all about and show some cards from Australian 32 pt. trial. He may be able to review a recovered AD patient or two.

He can and probably will make the case that this is still a risk but not a crap shoot like the old days.(see BP Amyloid backlash) AD will by far be perceived as the bigger disease and will draw more attention to the AVXL name and precision medicine processes.

Additionally, my guess is he will be doing a "late breaking" at AAIC and will have every opportunity to show the flag. If he makes the case for biomarker prescreen effectivity all BP will be like a bunch of 4 year old with their little faces pressed up against the window at the local cookie bakery. If I were Dr.M. I would hire someone to start my car for a few months.